Photocure ASA Reports Third Quarter Results with Notable Growth
Photocure ASA (OSE: PHO) has shared its financial results for the third quarter of 2024, showing significant growth in revenues from Hexvix/Cysview, amounting to NOK 120.1 million. This reflects an increase compared to NOK 107.3 million reported in the same quarter of 2023. The company's EBITDA also saw a rise to NOK 5.0 million, compared to NOK 3.3 million from last year. Photocure remains optimistic, reiterating its financial guidance for 2024, which includes a projected revenue growth of between 6% and 9% in constant currency along with positive EBITDA when excluding business development expenses.
Strong Performance and Future Outlook
Dan Schneider, the President and CEO of Photocure, expressed pride in the company’s solid performance during Q3. “We achieved a 12% revenue growth for Hexvix/Cysview and reported NOK 5.0 million in EBITDA. Our year-to-date product revenue growth stands at 9%. Regions such as North America and Europe contributed positively to our overall performance,” he stated.
Revenue Highlights and Strategic Partnerships
In total, Photocure generated group revenues of NOK 120.2 million this quarter, up from NOK 107.5 million in Q3 of the previous year. The total EBITDA for the group was NOK 5.0 million, reflecting the company’s strategic focus on its North American and European markets. The installed base of rigid blue light cystoscopy systems in the U.S. has grown to 387, marking a 13% increase since last year. Additionally, Photocure has established a strategic alliance with Richard Wolf GmbH aimed at creating an advanced flexible blue light cystoscope that will enhance bladder cancer detection.
Innovative Technology and Market Expansion
Through this partnership with Richard Wolf, Photocure intends to ensure that patients and physicians have reliable access to high-quality blue light cystoscopy equipment. Schneider highlighted the significance of this collaboration, stating, "The development project is already in progress with the ambition to launch a new flexible BLC system globally." The exploration of reclassifying BLC equipment from Class 3 to Class 2, as proposed by Karl Storz, is another development that Photocure is keenly observing.
Commitment to Bladder Cancer Care
Photocure firmly believes in the undeniable benefits of Blue Light Cystoscopy with Hexvix and Cysview, positioning it as a potential standard of care for bladder cancer management. The company anticipates continued consolidated revenue growth for 2024 and aims to install between 55 to 70 new flexible Saphira installations in the U.S.
Looking Ahead
Schneider concluded by emphasizing Photocure's steadfast position in the market. “Our ongoing growth combined with several initiatives aimed at accelerating Hexvix/Cysview adoption makes me confident that we can create significant value for our shareholders and the bladder cancer community in the months to come.”
Frequently Asked Questions
What financial results did Photocure report for Q3 2024?
Photocure reported Hexvix/Cysview revenues of NOK 120.1 million, with a total group revenue of NOK 120.2 million and an EBITDA of NOK 5.0 million.
What partnerships has Photocure formed recently?
Photocure has partnered with Richard Wolf GmbH to develop and commercialize a next-generation flexible blue light cystoscope.
What are the growth expectations for Photocure in 2024?
Photocure is expecting product revenue growth of 6% to 9% in constant currency for 2024, along with positive EBITDA excluding business development expenses.
How has the market presence of Photocure changed?
The installed base of rigid BLC systems in the U.S. has increased by 13% to a total of 387 systems.
What initiatives is Photocure undertaking to enhance patient care?
Photocure is focused on developing innovative technologies to improve bladder cancer detection and management, ensuring better healthcare outcomes for patients.
